The Europe’s Oncology Drug Development Landscape Market Intelligence Report is designed to Quickly Identify Active Oncology Drug Developers in the region, with their Drug Pipeline, Technologies, Management Expertise, Funding and Partnering capabilities.
Report covers the Largest set of Active Oncology Drug Developers in European Region; with their current late/early stage molecules available for partnering and thus stands out as a perfect market insights partnering and business development tool.
providing intelligence at fingertips
24 European Countries’ Covered
Oncology Drug Developers Insights
Individual Drug Mechanism of Action & Drug Target
Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies
INSIDE INTELLIGENCE - PREVIEW COPY
635 pages full of Insights
Molecule Type | The Report Highlights Active Drug Developers Developing |
|---|---|
Cellular Therapeutics | 89 European Cancer Drug Discovery Companies Developing – CAR-T / CAR-NK & other Cell based Therapies Targeting Cancer. (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Monoclonal Antibodies | 96 European Cancer Drug Discovery Companies Developing Monoclonal Antibodies against Tumor Antigens. (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Bispecific Antibodies & Bispecific T Cell Engagers | 42 European Cancer Drug Discovery Companies Developing Bispecific Antibodies & Bispecific T Cell Engagers. (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Antibody Drug Conjugates | 42 European Cancer Drug Discovery Companies Developing Antibody Drug Conjugates targeting Cancer. (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Cancer Vaccines | 65 European Cancer Drug Discovery Companies Developing Vaccines against Cancer. (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Kinase Inhibitors | 61 European Cancer Drug Discovery Companies Developing Small Molecule Kinase Inhibitors Targeting Cancer (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Targeted Protein Degraders | 22 European Cancer Drug Discovery Companies Developing Small Molecule Targeted Protein Degraders against Cancer (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Cancer Targeting Radiopharmaceuticals | 22 European Cancer Drug Discovery Companies Developing Cancer Targeting Radiopharmaceuticals. (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development) |
Oncolytic Viruses | 26 European Cancer Drug Discovery Companies Developing Oncolytic Viruses Based Cancer Targeting Drugs. (Intelligence covering Companies, Technologies & Molecules in Development) |
Microbiome &
Engineered Bacteria | 17 European Cancer Drug Discovery Companies Developing Microbiome & Engineered Bacteria Based Cancer Targeting Drugs (Intelligence covering Companies, Technologies & Molecules in Development) |
How Intelligence offered by OmicsX is different from other resources
Better Than Others
Comparisons | Europe Oncology Drug Development Landscape 2024 | Other Intelligence Sources |
|---|---|---|
Active Oncology Drug Developers | 635 Active Companies (Well Funded with clear defined clinical & early stage Pipeline) | 250-350 Companies (with many inactive and other domain companies) |
Oncology Drugs in Development | 1000+ Onco Targeting Drugs in Active Development(Complete Clinical & Preclinical Pipeline with indications, Drug Targets and Mechanism of Action) | 400 – 600 Cancer Targeting Drugs (mainly focuses on Clinical Stage molecules) |
Bio-Partnering Details | 800+ Oncology Deals complete details.(Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation) | Limited to Database / Resource Subscribed to.(Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals). |
Single Step Connect | Over 1500+ Key Decision Makers in 635 Companieswith valid emails and LinkedIn Accounts Links for one click contact. (Further CRMS Development Support is also available) | No Customized Solution Available in Market(Needs months of hard team work to prepare authentic business development tool. |
Trusted by
